Biomarker utilization in non-small cell lung cancer, are we treating after testing?

9609Background: Targeted therapy in EGFR and ALK mutated non-small cell lung cancer (NSCLC) has been the standard of care for nearly a decade with subsequent FDA approvals for ROS1 and BRAF V600 mu...